FIG. 7.

Treatment with caveola-inhibiting drugs does not prevent influenza virus infection. HeLa cells were treated with either 25 μg of nystatin/ml, 10 mM MβCD, or 100 μg of genistein/ml during both the adsorption and incubation periods of influenza virus infection. Influenza virus infection was detected with a monoclonal antibody against NP. (A) Indirect immunofluorescence analysis of 4-h influenza virus infection in drug-treated cells. (B) FACS analysis of entry assay infection in drug-treated cells. Key indicates treatment of cells. Background was determined by residual antibody staining on uninfected cells. (C) HeLa cells were transiently transfected with wild-type or dominant-negative caveolin-1 constructs before entry assay infection with influenza virus. Transfected cells are indicated by GFP expression; infection was monitored via indirect immunofluorescence using a monoclonal antibody against NP.